Binovi completes acquisition of Samurai Motion and its computer-aided vision therapy technology
CAVT is an extensive software package for developing eye tracking skills, visual thinking and processing skills, as well as binocular vision skills
Sector
Health
1090 stories · page 45 of 55
MagicMed Industries provides shareholder update as it launches new website
The company said the new website offers users a clean layout, a simple navigation structure and user-friendly functions
LeanLife Health says first containers of Mike Tyson-branded Iron Energy drink headed to its Arizona distribution facility
The product cleared US customs in Los Angeles on April 16
Binovi Technologies to buy vision therapy firm Samurai Motion Tracking in a C$2.5M all-stock deal
Samurai's Computer-Aided Vision Therapy is an extensive software package for developing eye tracking skills, visual thinking and processing skills, and binocular vision skills
Pathway Health on rapid growth pace for medical clinics to treat Canadians with chronic pain
Pathway Health president Wayne Cockburn says the firm’s Virtual Clinics division has the “largest medical cannabis telemedicine network in Canada,” serving over 50,000 patients
Algernon Pharmaceuticals announces topline data from Phase 2b part of its Phase 2b/3 coronavirus trial of Ifenprodil
The company said the purpose of the Phase 2b part was to identify one or more approvable FDA endpoints that showed a strong enough signal to consider moving forward into a Phase 3 study
Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre
Work will focus on supporting clinical trials related to therapies developed by both the hospital and Orgenesis, joint research, development of new approaches in advanced cell and gene therapies
Numinus Wellness closes "bought deal" financing of units for total gross proceeds $40.25M after full exercise of over-allotment option
The over-allotment option saw an additional 4,200,000 units purchased for additional gross proceeds of $5.25 million
Empower Clinics nets $12 million from warrant exercise, reveals expansion plans for KAI Medical Laboratory and Ontario clinics
CEO Steven McAuley told shareholders that the company "has never looked better"
Psyched Wellness submits patent application for AME-1
AME-1 is the company's proprietary extract from Amanita mushrooms, also known as Fly Agaric, which it says can be useful for preparations for human health
Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program
Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and an animal research pharmacokinetic study (VIRAL-A20-2)
Shield Therapeutics PLC takes bold approach in the US
Below we take a closer look at Shield Therapeutics...
Numinus Wellness is emerging as a clear leader in the booming psychedelics sector
The firm is the only Canadian public company licensed to work with the full range of psychedelics and to produce and extract psilocybin from mushrooms
Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies
Hear from executives at Aion Therapeutic, Lobe Sciences and Silo Pharma at Proactive's psychedelic-themed virtual showcase event on Tuesday February 23
Three companies pushing the field of psychedelic medicine forward to present at Proactive virtual conference on February 23
Hear executives from Silo Pharma and Lobe Sciences at Proactive's psychedelic-themed virtual showcase event on Tuesday, February 23
Psyched Wellness closes a bought deal private placement for total gross proceeds of $6,603,000
The company said the gross proceeds from the offering will be used to fully fund the pre-clinical trials of the company's Amanita Muscaria extract, AME-1 and to continue its scientific research of AME-1 and its potential benefits for people
MindMed launches Phase 1 study of potential LSD 'emergency off-switch' ketanserin
Studies have shown that administering ketanserin, a 5-HT2A receptor antagonist, before administering LSD almost completely prevents the psychedelic drug’s acute effects
Coronavirus: UK hits mid-February vaccination target, discusses vaccine proof for travellers to other countries
The new goal is to offer the first dose to another 2mln people by April while administering the booster to the 15mln inoculated so far
Revive Therapeutics closes previously announced bought deal offering for aggregate gross proceeds of $23M
The company said it intends to use the net proceeds for Phase 3 clinical costs for Bucillamine for coronavirus (COVID-19), Phase 1 clinical costs for Psilocybin for methamphetamine use disorder study, and other Psychedelic formulation de
MindMed seeks to harvest the power of psychedelics to treat mental health disorders
The New York City-based company has several projects in various stages from planning to ongoing clinical trials with a strong focus on legendary LSD